Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1.
Lancet
; 357(9257): 687-8, 2001 Mar 03.
Article
em En
| MEDLINE
| ID: mdl-11247556
Evidence suggests that nevirapine, a non-nucleoside reverse-transcriptase inhibitor, might be very effective in the prevention of HIV-1 integration and the reduction of risk of HIV-1 acquisition after exposure. We used a triple combination regimen, including nevirapine, for prophylaxis after occupational or sexual exposure to HIV-1 infection. Of 57 individuals who started therapy, only 41 returned for follow-up. Five had a grade three or four drug-induced hepatitis, two of whom also had a rash. This high rate of major adverse events raises concerns over the safety of such a regimen for its use in this population.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
HIV-1
/
Inibidores da Transcriptase Reversa
/
Fármacos Anti-HIV
/
Nevirapina
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Lancet
Ano de publicação:
2001
Tipo de documento:
Article
País de publicação:
Reino Unido